Last updated: February 27, 2026
What Is the Product?
NDC 00480-2044 represents Humira (adalimumab), a monoclonal antibody used primarily for autoimmune conditions. Its primary indications include rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and ankylosing spondylitis. The drug is marketed by AbbVie.
Market Landscape
Market Size and Key Drivers
The global biologics market, including adalimumab, was valued at approximately USD 238 billion in 2022, with a compound annual growth rate (CAGR) of 11% projected through 2030 (Grand View Research, 2022). Humira accounts for a significant portion of this market due to its broad indication profile and established patient base.
Competitive Environment
Main competitors include:
| Drug |
Class |
Market Share (2022) |
Key Indications |
| Humira (adalimumab) |
TNF-alpha inhibitor |
~22% (U.S.) |
Multiple autoimmune diseases |
| Enbrel (etanercept) |
TNF-alpha inhibitor |
~15% |
Rheumatoid arthritis, psoriasis |
| Stelara (ustekinumab) |
IL-12/IL-23 inhibitor |
~8% |
Crohn’s, psoriasis, psoriatic arthritis |
| Cosentyx (secukinumab) |
IL-17A inhibitor |
~4% |
Psoriasis, ankylosing spondylitis |
Humira remains the market leader, though biosimilar entries have eroded its market share outside the U.S.
Biosimilar Impact
European biosimilars launched in 2018 reduced prices by 20-35%. In the U.S., biosimilar approval occurred starting in 2023, with initial launches projected to lower list prices by 15-30%. The impact on revenue streams depends largely on market penetration and payer acceptance.
Regulatory and Patent Considerations
Humira’s initial patent expired in 2016, with secondary patents extending exclusivity until late 2023 in the U.S. [1]. The entry of biosimilars reduces revenue, prompting companies to develop next-generation biologics or new indications.
Price Trends and Projections
Historical Pricing Data
- U.S. List Price (2022): Approximately USD 5,800 per month per patient (including inflation adjustments).
- European List Price: About EUR 600-700 per month.
- Biosimilar Price Reduction: 20-35% in Europe; initial U.S. biosimilar launches expected to reduce list prices by approximately 15-25% in 2023–2025.
Current Market Prices (2023)
| Region |
Average Monthly Price (USD) |
Biosimilar Discount |
Post-Biosimilar Price Projection 2024-2026 |
| U.S. |
5,800 |
15-25% |
4,900 - 4,350 |
| EU |
4,200 |
20-30% |
2,940 - 3,360 |
Future Price Trends
- U.S. prices likely to decline by an additional 10-15% in the next 2 years due to increased biosimilar competition.
- Emerging markets will have lower prices, typically 60-70% of U.S. levels due to pricing regulations.
- Orphan and specialty indications will sustain higher price points for certain patient subsets, maintaining revenue even amid biosimilar competition.
Revenue and Market Share Projections
Revenue Estimates (2023–2028)
| Year |
Estimated Global Revenue (USD Billion) |
Notes |
| 2023 |
16.5 |
Post-patent expiry, biosimilar entry starting |
| 2024 |
14.8 |
Increased biosimilar penetration, price correction |
| 2025 |
13.7 |
Market stabilization, new indications drive growth |
| 2026 |
12.5 |
Market saturation, stable biosimilar presence |
Key Factors Affecting Revenue
- Biosimilar competition reduces price and volume.
- New indications and formulation improvements offset some revenue loss.
- Institutional and payer negotiations influence net prices.
Strategic Outlook
AbbVie continues to invest in pipeline development, targeting next-generation biologics and oral alternatives to mitigate biosimilar impact. The launch of biosimilars in the U.S. has initiated a decline trend, with the potential for stabilized revenues if new indications gain approval and market penetration increases.
Key Takeaways
- Humira (NDC 00480-2044) remains a dominant biologic but faces increasing biosimilar competition.
- Prices are projected to decline 15-25% in the U.S. annually over the next 2 years.
- Biosimilar entry impacts revenue by lowering list and net prices, especially outside the U.S.
- The global market remains sizable; development of new indications and formulations offers growth opportunities.
FAQs
1. What are the primary factors influencing Humira’s price decline?
Biosimilar competition, patent expirations, payer negotiations, and market saturation.
2. Will newer biologics replace Humira?
Some newer biologics with improved safety profiles and convenience may capture market share, but Humira's established efficacy and indications sustain its market position.
3. How do biosimilar prices compare globally?
European biosimilars typically discount prices by 20-35% relative to the originator; U.S. biosimilars are projected to discount by 15-25% initially.
4. How does Humira’s revenue trajectory look post-2023?
Revenue declines are expected due to biosimilar competition but will be mitigated by new indications and formulations.
5. What are the main challenges for biosimilar market penetration?
Brand recognition, payer acceptance, patent litigations, and market entry timing.
References
[1] U.S. Food and Drug Administration. (2023). Final patent settlement for Humira. https://www.fda.gov
